期刊文献+

杜氏肌营养不良基因突变检测国家参考品的研制 被引量:1

Development of national reference material for Duchenne muscular dystrophy gene mutation detection
下载PDF
导出
摘要 目的建立杜氏肌营养不良基因(DMD)突变检测国家参考品。方法收集DMD突变患儿及其家系血清,对建系成功的46份细胞系扩增繁殖至所需量后,进行基因组DNA提取并分装,制备成国家参考品。8家实验室采用8种二代测序(NGS)试剂和2种多重连接依赖性探针扩增试剂(MLPA)对候选参考品进行了验证。通过NGS和MLPA试剂检测候选参考品评价参考品的均匀性。通过NGS试剂对反复冻融3次后的候选参考品进行检测以评价稳定性。结果4家实验室采用MLPA试剂的检测结果一致,8家实验室采用NGS试剂的检测结果基本一致,对于突变位点信息有争议的参考品,采用一代测序进行了测序验证。NGS和MLPA各自均匀性检测结果均一致,反复冻融3次后的检测结果与常规保存的检测结果一致。结论通过协作验证以及均匀性、稳定性分析,成功建立了DMD突变检测国家参考品,该参考品可用于DMD基因突变检测试剂盒的性能评价。 Objective To establish a national reference for the detection of Duchenne muscular dystrophy(DMD)gene mutation.Methods Serum samples from children with DMD gene mutation and their families were collected,and 46 successfully established cell lines were expanded and multiplied to the required amount.Genomic DNA was extracted and aliquoted to prepare national reference materials.The candidate reference was validated with 8 next⁃generation sequencing(NGS)kits and 2 multiplex ligation dependent probe amplification(MLPA)kits from 8 manufacturers.The candidate reference was detected by the NGS kit and MLPA kit to evaluate the homogeneity.The stability of the candidate reference was evaluated by the NGS kit after repeated freezing and thawing three times.Results The results of four laboratories using MLPA kits were consistent,and the results of eight laboratories using NGS kits were basically the same.For the candidate reference with controversial mutation site information,the first⁃generation sequencing was used for sequencing verification.The homogeneity test results of NGS and MLPA were consistent,and the stability results were consistent with the results of conventional preservation.Conclusion Through collaborative verification,homogeneity and stability analysis,the national reference for DMD gene mutation detection was successfully established,which can be used for performance evaluation of DMD gene mutation detection kits.
作者 于婷 孙楠 孙晶 黄杰 曲守方 YU Ting;SUN Nan;SUN Jing;HUANG Jie;QU Shoufang(National Institutes for Food and Drug Control,Beijing,China,100050)
出处 《分子诊断与治疗杂志》 2021年第8期1205-1208,共4页 Journal of Molecular Diagnostics and Therapy
基金 国家重点研发计划(2018YFC1002400)。
关键词 杜氏肌营养不良基因 国家参考品 二代测序法 多重连接依赖性探针扩增 Duchenne muscular dystrophy gene mutation DMD National reference material Next generation sequencing Multiplex ligation dependent probe amplification
  • 相关文献

参考文献13

二级参考文献35

  • 1Ivan Fai-man Lo,Kent Keung-san Lai,Tony Ming-for Tong,Stephen Tak-sum Lam.A different spectrum of DMD gene mutations in local Chinese patients with Duchenne/Becker muscular dystrophy[J].Chinese Medical Journal,2006(13):1079-1087. 被引量:21
  • 2Bushby K, Finkel R, Birnkrant D J, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1 : diagnosis, and pharmacological and psychosocial management [ J ]. Lancet Neurol, 2010, 9 ( 1 ) : 77-93. DO!: 10. 1016/S1474-4422 (09)70271-6.
  • 3Engel AG, Franzini-Armatrong C. Myology [ M ]. 3rd ed. New York : McGraw-Hill Inc, 2004 : 961-1025.
  • 4Zhang H, Zhu Y, Sun Y, et al. Serum creatinine level: a supplemental index to distinguish Duchenne muscular dystrophy from Becker muscular dystrophy [ J ]. Dis Markers, 2015, 2015 : 141856. DOI: 10. 1155/2015/141856.
  • 5Wagner KR, Lechtzin N, Judge DP. Current treatment of adult Duchenne muscular dystrophy[ J]. Bioehim Biophys Aeta, 2007, 1772 (2) : 229-237. DOI : 10. 1016/j. bbadis. 2006.06. 009.
  • 6Li X, Zhao L, Zhou S, et al. A comprehensive database of Duchenne and Becket muscular dystrophy patients (0-18 years old) in East China[J]. Orphanet J Rare Dis, 2015, 10: 5. DOI: 10. 1186/s13023-014-0220-7.
  • 7Yang J, Li SY, Li YQ, et al. MLPA-based genotype-phenotype analysis in 1053 Chinese patients with DMD/BMD[ J]. BMC Med Genet, 2013, 14: 29. DOI: 10. 1186/1471-2350-14-29.
  • 8Chen WJ, Lin QF, Zhang QJ, et al. Molecular analysis of the dystrophin gene in 407 Chinese patients with Duchenne/Becker muscular dystrophy by the combination of multiplex ligation- dependent probe amplification and Sanger sequencing [ J ]. C/in Chim Acta, 2013, 423 : 35-38. DOI: 10. 1016/j. cca. 2013.04. 006.
  • 9Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duehenne muscular dystrophy, part 2: implementation of muhidiseiplinary care [ J ]. Lancet Neurol, 2010, 9 (2) : 177-189. DOI : 10. 1016/S1474-4422 ( 09 ) 70272- 8.
  • 10Bowles DE, McPhee SW, Li C, et al. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector[J]. Mol Ther, 2012, 20(2) : 443-455. DOI: 10. 1038/ mt. 2011. 237.

共引文献102

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部